Earnings
Since taking over the helm of GlaxoSmithKline, Emma Walmsley has been driving changes at the company with a heavy focus on pharma R&D. Today, Walmsley and R&D Head Hal Barron unveiled a long-term plan for R&D that is focused on the immune system and genetics.
Biogen reported strong sales for the second quarter, with total revenues of $3.4 billion, up 9 percent compared to the same period in 2017.
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.
Cowen Research’s biotech team published a recent report and concluded that investors would have better luck ignoring—or even doing the complete opposite—of what equity analysts advise.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Nabriva Therapeutics reported positive topline results from its Phase III clinical trial of oral lefamulin compared to oral moxifloxacin in adults with moderate community-acquired bacterial pneumonia (CABP).
You know when an analyst starts an article with, “Gilead’s Q1 financial results were a disaster,” that it requires a closer look.
Valeant Pharmaceuticals will change its name to Bausch Health Companies Inc. in July of this year. The company will rebrand itself with the highly recognizable name of its subsidiary eye-care company Bausch + Lomb.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
Ironwood Pharmaceuticals will split into two independent companies, Ironwood and what is currently being dubbed R&D Co.
PRESS RELEASES